The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Razelle Kurzrock

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)

The University of Texas MD Anderson Cancer Center

Houston

Texas

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. 2001 - 2012
  • Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, USA. 2003 - 2007
  • Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, USA. 2003

References

  1. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan-Linnell, S.K., Urien, S., Mani, S., Chaudhary, I., Ghalib, M.H., Buchbinder, A., Lokiec, F., Mulcahy, M. Cancer (2012) [Pubmed]
  2. Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors. Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., Sarantopoulos, J. Mol. Cancer Ther. (2012) [Pubmed]
  3. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Angelo, L.S., Wu, J.Y., Meng, F., Sun, M., Kopetz, S., McCutcheon, I.E., Slopis, J.M., Kurzrock, R. Mol. Cancer Ther. (2011) [Pubmed]
  4. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Kurzrock, R., Sherman, S.I., Ball, D.W., Forastiere, A.A., Cohen, R.B., Mehra, R., Pfister, D.G., Cohen, E.E., Janisch, L., Nauling, F., Hong, D.S., Ng, C.S., Ye, L., Gagel, R.F., Frye, J., Müller, T., Ratain, M.J., Salgia, R. J. Clin. Oncol. (2011) [Pubmed]
  5. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., Eckhardt, S.G., Eid, J.E., Greig, G., Habben, K., McCarthy, C.D., Gore, L. Clin. Cancer Res. (2010) [Pubmed]
  6. Project Zero Delay: a process for accelerating the activation of cancer clinical trials. Kurzrock, R., Pilat, S., Bartolazzi, M., Sanders, D., Van Wart Hood, J., Tucker, S.D., Webster, K., Mallamaci, M.A., Strand, S., Babcock, E., Bast, R.C. J. Clin. Oncol. (2009) [Pubmed]
  7. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Kurzrock, R., Kantarjian, H.M., Blascovich, M.A., Bucher, C., Verstovsek, S., Wright, J.J., Pilat, S.R., Cortes, J.E., Estey, E.H., Giles, F.J., Beran, M., Sebti, S.M. Clin. Cancer Res. (2008) [Pubmed]
  8. Cutaneous castleman's disease responds to anti interleukin-6 treatment. Ahmed, B., Tschen, J.A., Cohen, P.R., Zaki, M.H., Rady, P.L., Tyring, S.K., Corringham, R.E., Kurzrock, R. Mol. Cancer Ther. (2007) [Pubmed]
  9. Studies in target-based treatment. Kurzrock, R. Mol. Cancer Ther. (2007) [Pubmed]
  10. I have good news! You have leukemia. Kurzrock, R. Clin. Dermatol. (2007) [Pubmed]
  11. Studies in target-based treatment. Kurzrock, R. Mol. Cancer Ther. (2007) [Pubmed]
  12. Purine analogues in advanced T-cell lymphoid malignancies. Kurzrock, R., Ravandi, F. Semin. Hematol. (2006) [Pubmed]
  13. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Kurzrock, R., Talpaz, M., Li, L., Estrov, Z. Leuk. Lymphoma (2006) [Pubmed]
  14. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. Kurzrock, R. Clin. Cancer Res. (2005) [Pubmed]
  15. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. Kurzrock, R., Albitar, M., Cortes, J.E., Estey, E.H., Faderl, S.H., Garcia-Manero, G., Thomas, D.A., Giles, F.J., Ryback, M.E., Thibault, A., De Porre, P., Kantarjian, H.M. J. Clin. Oncol. (2004) [Pubmed]
  16. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Kurzrock, R., Kantarjian, H.M., Druker, B.J., Talpaz, M. Ann. Intern. Med. (2003) [Pubmed]
  17. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Kurzrock, R., Kantarjian, H.M., Cortes, J.E., Singhania, N., Thomas, D.A., Wilson, E.F., Wright, J.J., Freireich, E.J., Talpaz, M., Sebti, S.M. Blood (2003) [Pubmed]
  18. Therapy of T cell lymphomas with pentostatin. Kurzrock, R. Ann. N. Y. Acad. Sci. (2001) [Pubmed]
  19. Cytokine deregulation in cancer. Kurzrock, R. Biomed. Pharmacother. (2001) [Pubmed]
 
WikiGenes - Universities